Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?CTLA-4PD-L1PD-1Immune checkpoint inhibitor therapiesImmunotherapiesBiomarkersNeoantigensAlthough durable clinical responses are achieved in a significant number of patients given ...
However, the negative results of the phase III clinical trial of the would-be first-in-class IDO1 inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in patients with advanced malignant melanoma call for a better understanding of the role of IDO1 inhibition. In ...
However, the negative results of the phase III clinical trial of the would-be first-in-class IDO1 inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in patients with advanced malignant melanoma call for a better understanding of the role of IDO1 inhibition. In ...
Its role in the immune response against cancer is controversial. Finally, a subset of CD4+ T cells called regulatory T cells (Tregs) and characterized by the expression of CD25 and Foxp3, inhibit the immune response and represent a widely described mechanism whereby the tumor can escape the ...
Single-cell RNA sequencing (scRNA-seq) is a tool for studying gene expression at the single-cell level that has been widely used due to its unprecedented high resolution. In the present review, we outline the preparation process and sequencing platforms for the scRNA-seq analysis of solid tumor...
T-VEC is currently being evaluated as a potential treatment in melanoma and other advanced cancers [19, 20]. In a pre-clinical study in breast cancer bearing mice, the combination of an anti-PD1 antibody and a multi-peptide vaccine prolonged the vaccine-induced progression-free survival (PFS)...
Since ZIKV shares the mosquito host with a number of other flavivirus species, it is in principle possible that re- combinations have taken place between the viral RNA ge- nomes of different species, although Musso and Gubler considered this an unlikely scenario [9]. Recombinations have been ...
(4) The optimal function of T cells is determined by immune balance between all these factors, such that a T cell may preserve its ability to kill its target cells, to produce cytokines, and to migrate whilst preventing exhaustion and death. The reason why cancer cells may grow in an ...
as those tumor progressions with a minimum two-fold increase in tumor growth rate (TGR) after initiation of therapy compared to the pretherapy TGR [24]. In this study, 218 patients with different types of cancers were treated with anti-PD1 or anti-PD-L1 antibody monotherapy. Among 131 ...
However, the negative results of the phase III clinical trial of the would-be first-in-class IDO1 inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in patients with advanced malignant melanoma call for a better understanding of the role of IDO1 inhibition. In ...